Glioblastoma: State of the Art and Future Perspectives

Guest Editors:

Prof. Dr. Ghazaleh Tabatabai

Dr. Hiroaki Wakimoto
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02215, USA

Deadline for manuscript submissions:
closed (31 December 2018)

Message from the Guest Editors

Glioblastoma is one of the most common types of primary cancer in the central nervous system. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the entry of novel highthroughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Here, we aim at updating researchers and clinicians to provide a systemic view on glioblastoma by highlighting the progress made in basic, preclinical and clinical research and outlining future challenges. To this end, we welcome articles on basic, preclinical and clinical research in glioblastoma. In addition, we will present invited review articles on the topics of neurosurgical approaches, neuropathology and genetics, preclinical research and mouse models of glioblastoma, imaging, radiation therapy and tumor-treating fields, alkylating chemotherapy, immunotherapy, investigational therapies and precision oncology trials in glioblastoma.

mdpi.com/si/14537

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us